Hyperion DeFi, Inc. (NASDAQ:HYPD) Receives $4.58 Consensus Target Price from Analysts

Hyperion DeFi, Inc. (NASDAQ:HYPD) has been given a consensus recommendation of “Hold” by the four analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and two have given a buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $5.8750.

A number of research firms recently issued reports on HYPD. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Hyperion DeFi in a research note on Thursday, January 22nd. Wall Street Zen upgraded Hyperion DeFi from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. Cantor Fitzgerald began coverage on Hyperion DeFi in a report on Tuesday, December 16th. They issued an “overweight” rating and a $4.00 price target for the company. Zacks Research raised shares of Hyperion DeFi to a “hold” rating in a research report on Monday, December 29th. Finally, Chardan Capital set a $7.75 target price on shares of Hyperion DeFi and gave the company a “buy” rating in a report on Wednesday, December 24th.

Insider Activity

In other news, CFO David R. Knox bought 27,950 shares of Hyperion DeFi stock in a transaction dated Wednesday, December 31st. The shares were acquired at an average cost of $3.59 per share, with a total value of $100,340.50. Following the completion of the transaction, the chief financial officer owned 327,950 shares in the company, valued at approximately $1,177,340.50. This trade represents a 9.32% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ellen R. Strahlman purchased 11,856 shares of Hyperion DeFi stock in a transaction that occurred on Monday, December 29th. The stock was acquired at an average cost of $3.61 per share, with a total value of $42,800.16. Following the acquisition, the director directly owned 34,869 shares of the company’s stock, valued at $125,877.09. The trade was a 51.52% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought 58,830 shares of company stock valued at $213,424 in the last ninety days. Company insiders own 10.86% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Sanctuary Advisors LLC acquired a new stake in shares of Hyperion DeFi during the 4th quarter valued at about $38,000. Nations Financial Group Inc. IA ADV acquired a new stake in Hyperion DeFi in the 4th quarter valued at approximately $40,000. Price T Rowe Associates Inc. MD bought a new position in Hyperion DeFi in the 4th quarter worth approximately $73,000. Formidable Asset Management LLC bought a new position in Hyperion DeFi in the 4th quarter worth approximately $83,000. Finally, State Street Corp acquired a new position in shares of Hyperion DeFi during the fourth quarter worth approximately $92,000. Institutional investors and hedge funds own 25.84% of the company’s stock.

Hyperion DeFi Stock Performance

Shares of HYPD stock opened at $3.27 on Monday. The firm has a 50 day moving average of $3.46 and a two-hundred day moving average of $5.39. The company has a quick ratio of 2.25, a current ratio of 2.25 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $26.72 million, a PE ratio of -0.81 and a beta of 2.74. Hyperion DeFi has a 52 week low of $0.85 and a 52 week high of $17.18.

About Hyperion DeFi

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.